Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

RAF inhibitor therapy yields significant reductions in tumour burden in the majority of V600E-positive melanoma patients; however, resistance occurs within 2–18 months. Here we demonstrate that the mixed lineage kinases (MLK1–4) are MEK kinases that reactivate the MEK/ERK pathway in the presence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Marusiak, Anna A., Edwards, Zoe C., Hugo, Willy, Trotter, Eleanor W., Girotti, Maria R., Stephenson, Natalie L., Kong, Xiangju, Gartside, Michael G., Fawdar, Shameem, Hudson, Andrew, Breitwieser, Wolfgang, Hayward, Nicholas K., Marais, Richard, Lo, Roger S., Brognard, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046110/
https://www.ncbi.nlm.nih.gov/pubmed/24849047
http://dx.doi.org/10.1038/ncomms4901

Ejemplares similares

Ejemplares similares